Jason Harris

Senior Editor, OncLive®
Jason Harris has worked in journalism for more than 20 years, including stints at daily newspapers and niche publications for oncology and cardiology. He is a senior editor for OncologyLive® and managing editor for Oncology Fellows and the annual Giants of Cancer Care® album. He also contributes to the OncLive On Air and OncFellows podcasts. Email: jharris@onclive.com


Hispanic Ethnicity Associated With Poorer OS in Pediatric Neuroblastoma

May 26th 2022

Non-White Hispanic children and those with public insurance care in a clinical trial for high-risk neuroblastoma had inferior overall survival rates compared with other children.

NICE Recommends Pembrolizumab Plus Chemotherapy for Metastatic PD-L1–Positive TNBC

May 26th 2022

The United Kingdom’s National Institute for Health and Care Excellence has issued draft guidance recommending the approval of pembrolizumab plus chemotherapy for the treatment of patients with PD-L1–positive metastatic triple-negative breast cancer.

AUA, ASTRO Issue Updated Guidelines for Clinically Localized Prostate Cancer

May 17th 2022

The American Urologic Association in collaboration with the American Society for Radiation Oncology has issued new practice guidelines for the management of clinically localized prostate cancer.

Tisagenlecleucel Approved in Europe for Relapsed/Refractory Follicular Lymphoma

May 17th 2022

The European Commission has approved the CD19-targeting chimeric antigen receptor T-cell agent tisagenlecleucel for the treatment of adults with relapsed/refractory follicular lymphoma following at least 2 lines of systemic therapy.

Novartis Suspends Production of Radioligand Therapy Agents in New Jersey and Italy

May 9th 2022

Pharmaceutical giant Novartis has temporarily halted radioligand therapy production at sites in Millburn, New Jersey, and Ivrea, Italy, citing potential quality issues in its manufacturing processes.

HER2 Expression Is a Key Determinant of Trastuzumab Deruxtecan Activity

May 8th 2022

HER2 expression appeared to be a significant predictor for response to fam-trastuzumab deruxtecan-nxki, according to findings from a biomarker analysis of patients with metastatic breast cancer in the phase 2 DAISY trial.

NCCN Establishes Standards of Care in Ampullary Adenocarcinoma

April 29th 2022

The National Comprehensive Cancer Network has released new guidelines for ampullary adenocarcinoma, a disease accounting for just 0.2% of all gastrointestinal malignancies.

NCCN Recommends Fifth COVID-19 Shot for Patients with Cancer

April 29th 2022

The National Comprehensive Cancer Network is advising individuals who are immunocompromised, including those with cancer, to receive a fifth COVID-19 vaccination.

Four Baseline Characteristics Predict CR/sCR in Multiple Myeloma

April 25th 2022

Investigators have identified immunoglobulin G heavy chain, soluble B-cell maturation agent, prothrombin time and international normalized ratio, and high vector copy number in drug product as predictors for response in patients with multiple myeloma.

Abatacept Reduces Graft Vs Host Disease, Prednisone Use Following Stem Cell Transplant

April 24th 2022

Abatacept significantly reduced steroid-refractory chronic graft versus host disease and the use of prednisone following allogeneic hematopoietic stem cell transplantation.

Runyon Foundation Issues $3.6 Million in Grants to Early Career Investigators

April 22nd 2022

The Damon Runyon Cancer Research Foundation awarded a total of $3.6 million to 9 winners of the Damon Runyon-Rachleff Innovation Awards. The grants support investigators whose ideas have the potential to significantly advance the prevention, diagnosis, or treatment of cancer.

Investigators Hope to Build on Early Efficacy in KRAS G12C-Mutated CRC

April 14th 2022

Investigators have explored the potential of KRAS inhibition in patients with colorectal cancer, and early results have established the pathway as a prime target for drug development.

gLOH-High Status Is Associated With Enhanced Response to Talazoparib in mCRPC

April 11th 2022

High genomic loss of heterozygosity scores may serve as a predictive marker for response to treatment with talazoparib in metastatic castration-resistant prostate cancer.

NK Cells Plus Bispecific Antibody Delivers Strong Results in Advanced Lymphoma

April 10th 2022

The innate cell engager AMF13 combined with preactivated and expanded natural killer (NK) cells induced “very encouraging activity” in patients with heavily pretreated lymphoma.

Temferon Displays Activity in Glioblastoma

April 8th 2022

Temferon, genetically modified Tie2-expressing monocytes targeting interferona2, showed the potential to activate the immune system and reprogram the tumor microenvironment in patients with glioblastoma.

NICE Makes Avelumab Available for Maintenance Treatment of Urothelial Cancer

April 8th 2022

Avelumab is now a treatment option for patients with urothelial cancer in the United Kingdom following a recommendation from the National Institute for Health and Care Excellence issued Thursday, April 7, 2022.1

Smile, Be Happy, and Work Hard

April 1st 2022

Evan B. Shereck, MD, MEd, talks about working with families experiencing incredible stress, the importance of wellness for both physicians and their partners, and making medical learning fun.

CAR T-Cell Therapy May Represent a New Option in Medullary Thyroid Cancer

April 1st 2022

Investigators at the Perelman School of Medicine at the University of Pennsylvania have recently initiated a clinical trial evaluating a novel CAR T-cell therapy in an effort to fill an unmet need for systemic treatment for patients with advanced incurable medullary thyroid cancer.

James Allison, PhD, to Lead New Immunotherapy Unit at MD Anderson

March 24th 2022

James P. Allison, PhD, a Nobel Laureate and Giants of Cancer Care® award winner, will head up the new James P. Allison Institute at The University of Texas MD Anderson Cancer Center.

Neoadjuvant Niraparib Shows Early Promise in BRCA-Mutated, HRD+ Ovarian Cancer

March 19th 2022

Neoadjuvant niraparib induced strong results for patients with BRCA-mutant, homologous repair deficient–positive advanced resectable ovarian cancer.